Estrella Immunopharma Net Income From Continuing Ops Over Time
| ESLAW Stock | 0.09 0 3.53% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. Estrella |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Estrella Immunopharma. If investors know Estrella will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Estrella Immunopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Return On Assets (1.75) |
The market value of Estrella Immunopharma is measured differently than its book value, which is the value of Estrella that is recorded on the company's balance sheet. Investors also form their own opinion of Estrella Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Estrella Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Estrella Immunopharma's market value can be influenced by many factors that don't directly affect Estrella Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Estrella Immunopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Estrella Immunopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Estrella Immunopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income From Continuing Ops Analysis
Compare Estrella Immunopharma and related stocks such as Snap On, Mannatech Incorporated, and Church Dwight Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SNA | 189.8 M | 279.2 M | 312 M | 359.5 M | 431.4 M | 489.3 M | 557.1 M | 571 M | 695.5 M | 710.3 M | 646.1 M | 841.4 M | 933.9 M | 1 B | 632.6 M |
| MTEX | (17.4 M) | (20.7 M) | (1.4 M) | 3.2 M | 6.5 M | 5.8 M | (586 K) | (1.8 M) | (3.9 M) | 3.3 M | 6.3 M | 9.8 M | (4.5 M) | (7 M) | (6.6 M) |
| CHD | 270.7 M | 309.6 M | 349.8 M | 394.4 M | 413.9 M | 410.4 M | 459 M | 743.4 M | 568.6 M | 615.9 M | 785.9 M | 827.5 M | 413.9 M | 437.2 M | 550 M |
| SHOO | 97.2 M | 97.2 M | 119.6 M | 133.3 M | 112.6 M | 113.7 M | 121.3 M | 119.1 M | 130.5 M | 141.7 M | (18.3 M) | 192.5 M | 217.2 M | 168.9 M | 139.6 M |
| PG | 10.9 B | 9.3 B | 11.4 B | 11.7 B | 8.9 B | 10 B | 10.2 B | 9.9 B | 4 B | 13.1 B | 14.4 B | 14.8 B | 14.7 B | 15 B | 12.5 B |
| NWL | 292.8 M | 170.4 M | 732.2 M | 664.3 M | 551.2 M | 415.7 M | 1.1 B | 2.7 B | (6.8 B) | 186.1 M | (770 M) | 572 M | 197 M | (551 M) | (523.5 M) |
| MNTK | 28.8 M | 28.8 M | 28.8 M | 28.8 M | 28.8 M | 28.8 M | 28.8 M | 28.8 M | 28.8 M | 5.8 M | 4.6 M | (4.5 M) | 35.2 M | 16.1 M | 15.8 M |
Estrella Immunopharma and related stocks such as Snap On, Mannatech Incorporated, and Church Dwight Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Estrella Immunopharma | ESLAW |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
null 0.091
Additional Tools for Estrella Stock Analysis
When running Estrella Immunopharma's price analysis, check to measure Estrella Immunopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Estrella Immunopharma is operating at the current time. Most of Estrella Immunopharma's value examination focuses on studying past and present price action to predict the probability of Estrella Immunopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Estrella Immunopharma's price. Additionally, you may evaluate how the addition of Estrella Immunopharma to your portfolios can decrease your overall portfolio volatility.